---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026205"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:24:15.249265+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DiaMedica Therapeutics Reports Q2 2025 Financial Results and Positive Phase 2 Interim Data for DM199 in Preeclampsia

## Summary
- Phase 2 Part 1a interim data (n=28) showed statistically significant reductions in blood pressure and uterine artery pulsatility index with no placental transfer of DM199.
- Raised $30.1 million in July 2025 private placement, extending proforma cash to ~$60M and funding operations into H2 2027.
- ReMEDy2 Phase 2/3 trial for acute ischemic stroke enrollment progressing; interim analysis on first 200 patients expected Q2 2026.
- Appointed Julie Krop, MD, as Chief Medical Officer in August 2025; added to Russell 2000 and 3000 Indexes in June 2025.
- Net loss for Q2 2025 was $7.7 million, up from $5.1 million in Q2 2024; R&D expenses increased to $5.8 million.

## SEC filing metadata
- accession: 0001437749-25-026205
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774925026205/0001437749-25-026205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774925026205/dmtp20250811_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026205
- JSON: https://secwatch.observer/filing/0001437749-25-026205.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.